Zydus Lifesciences is currently trading at Rs. 469.30, up by 3.75 points or 0.81% from its previous closing of Rs. 465.55 on the BSE.
The scrip opened at Rs. 469.95 and has touched a high and low of Rs. 472.00 and Rs. 463.35 respectively. So far 6591 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 472.00 and Rs. 452.20 respectively. The current market cap of the company is Rs. 47477.44 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 16.21% and 8.81% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Apixaban Tablets, 2.5 mg and 5 mg (USRLD: Eliquis Tablets).
Apixaban blocks the activity of certain clotting substances in the blood. It is used to lower the risk of stroke or a blood clot in people with a heart rhythm disorder called atrial fibrillation. It is also used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery. It is also used for treatment of blood clots in the veins of legs or lungs, and reduces the risk of them occurring again. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad (India).
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of $18,876 million in the United States (IQVIA MAT Dec. 2022). The group now has 347 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.